Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:AVTE NASDAQ:HUMA NASDAQ:KPTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.95-1.0%$1.72$1.05▼$5.17$211.25M0.27968,199 shs2.24 million shsAVTEAerovate Therapeutics$7.76+2.4%$8.24$56.35▼$105.00$224.92M0.9512,438 shs53,233 shsHUMAHumacyte$1.47-2.0%$2.01$1.15▼$6.77$232.80M1.873.93 million shs1.17 million shsKPTIKaryopharm Therapeutics$6.45-2.9%$5.20$3.51▼$16.95$55.93M0.35124,840 shs65,890 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-3.43%-4.83%+20.12%+34.01%+66.95%AVTEAerovate Therapeutics-0.59%+1.07%+2.36%+9.15%-88.73%HUMAHumacyte+1.35%+2.74%-16.43%-36.71%-73.64%KPTIKaryopharm Therapeutics+6.92%-1.48%+65.17%+51.25%-39.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.95-1.0%$1.72$1.05▼$5.17$211.25M0.27968,199 shs2.24 million shsAVTEAerovate Therapeutics$7.76+2.4%$8.24$56.35▼$105.00$224.92M0.9512,438 shs53,233 shsHUMAHumacyte$1.47-2.0%$2.01$1.15▼$6.77$232.80M1.873.93 million shs1.17 million shsKPTIKaryopharm Therapeutics$6.45-2.9%$5.20$3.51▼$16.95$55.93M0.35124,840 shs65,890 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-3.43%-4.83%+20.12%+34.01%+66.95%AVTEAerovate Therapeutics-0.59%+1.07%+2.36%+9.15%-88.73%HUMAHumacyte+1.35%+2.74%-16.43%-36.71%-73.64%KPTIKaryopharm Therapeutics+6.92%-1.48%+65.17%+51.25%-39.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.11Buy$8.71346.89% UpsideAVTEAerovate Therapeutics 0.00N/AN/AN/AHUMAHumacyte 2.88Moderate Buy$9.75563.27% UpsideKPTIKaryopharm Therapeutics 2.80Moderate Buy$34.00427.13% UpsideCurrent Analyst Ratings BreakdownLatest KPTI, ACRS, HUMA, and AVTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025HUMAHumacyteBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$3.508/27/2025HUMAHumacyteBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$3.508/12/2025HUMAHumacyteTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $3.508/12/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.008/12/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$42.00 ➝ $25.008/11/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/23/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/16/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/11/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.007/10/2025ACRSAclaris TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$6.007/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$16.79M12.58N/AN/A$1.44 per share1.35AVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AHUMAHumacyte$1.57M148.28N/AN/A($0.41) per share-3.59KPTIKaryopharm Therapeutics$137.27M0.41N/AN/A($22.10) per share-0.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$132.07M-$1.37N/AN/AN/A-802.03%-34.01%-24.18%11/5/2025 (Estimated)AVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%11/10/2025 (Estimated)HUMAHumacyte-$148.70M-$0.45N/AN/AN/AN/AN/A-78.26%11/14/2025 (Estimated)KPTIKaryopharm Therapeutics-$76.42M-$14.59N/AN/AN/A-90.02%N/A-84.28%11/4/2025 (Estimated)Latest KPTI, ACRS, HUMA, and AVTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025HUMAHumacyte-$0.15-$0.24-$0.09-$0.24$0.94 million$0.30 million8/11/2025Q2 2025KPTIKaryopharm Therapeutics-$3.80-$4.32-$0.52-$4.32$37.92 million$37.93 million8/7/2025Q2 2025ACRSAclaris Therapeutics-$0.13-$0.13N/A-$0.13$1.34 million$1.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A3.883.88AVTEAerovate TherapeuticsN/A8.788.78HUMAHumacyte2.972.451.93KPTIKaryopharm TherapeuticsN/A0.990.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%AVTEAerovate TherapeuticsN/AHUMAHumacyte44.71%KPTIKaryopharm Therapeutics66.44%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.60%AVTEAerovate Therapeutics24.90%HUMAHumacyte5.10%KPTIKaryopharm Therapeutics2.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.33 million102.27 millionOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableHUMAHumacyte150158.37 million150.30 millionOptionableKPTIKaryopharm Therapeutics3808.67 million8.41 millionOptionableKPTI, ACRS, HUMA, and AVTE HeadlinesRecent News About These CompaniesKaryopharm Therapeutics Inc.: Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in MyelofibrosisSeptember 10 at 6:56 PM | finanznachrichten.deKaryopharm completes enrollment in Phase 3 Sentry trialSeptember 10 at 6:56 PM | msn.comKaryopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in MyelofibrosisSeptember 10 at 7:00 AM | prnewswire.comAdage Capital Partners GP L.L.C. Lowers Stake in Karyopharm Therapeutics Inc. $KPTISeptember 10 at 3:44 AM | marketbeat.comBirchview Capital LP Decreases Stake in Karyopharm Therapeutics Inc. $KPTISeptember 4, 2025 | marketbeat.comPalo Alto Investors LP Has $1.21 Million Holdings in Karyopharm Therapeutics Inc. $KPTISeptember 4, 2025 | marketbeat.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2025 | prnewswire.com139,646 Shares in Karyopharm Therapeutics Inc. $KPTI Acquired by T. Rowe Price Investment Management Inc.August 28, 2025 | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 23, 2025 | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comKaryopharm’s Earnings Call: Clinical Wins Amid Financial StrainAugust 13, 2025 | msn.comKaryopharm Therapeutics Inc.: Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company ProgressAugust 12, 2025 | finanznachrichten.deKaryopharm Therapeutics: Q2 Earnings SnapshotAugust 12, 2025 | chron.comKaryopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue EstimatesAugust 11, 2025 | zacks.comKaryopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call TranscriptAugust 11, 2025 | seekingalpha.comKaryopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company ProgressAugust 11, 2025 | prnewswire.comKaryopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To ExpectAugust 10, 2025 | finance.yahoo.comEarnings Outlook For Karyopharm TherapeuticsAugust 8, 2025 | benzinga.comKaryopharm to Report Second Quarter 2025 Financial Results on August 11, 2025August 5, 2025 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | prnewswire.comKaryopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseJuly 29, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKPTI, ACRS, HUMA, and AVTE Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.95 -0.02 (-1.02%) Closing price 04:00 PM EasternExtended Trading$1.96 +0.01 (+0.46%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Aerovate Therapeutics NASDAQ:AVTE$7.76 +0.19 (+2.44%) As of 09/11/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Humacyte NASDAQ:HUMA$1.47 -0.03 (-2.00%) Closing price 04:00 PM EasternExtended Trading$1.47 +0.00 (+0.07%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Karyopharm Therapeutics NASDAQ:KPTI$6.45 -0.19 (-2.86%) Closing price 04:00 PM EasternExtended Trading$6.50 +0.05 (+0.85%) As of 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Why Micron Stock Could Outperform NVIDIA in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
